Trial Profile
LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy for Stage III Colon Cancer Patients Treated in Adjuvant Setting: Impact on Oxaliplatin-induced Sensitive Neurotoxicity. A Multicenter Phase II Randomized Trial (LEANOX)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer
- Focus Adverse reactions
- Acronyms LEANOX
- 21 Jan 2023 Results assessing whether the oxaliplatin dose adaptation based on the Lean Body Mass index can reduce neurotoxicity, in patients treated for a stage III colorectal cancer, presented at the 2023 Gastrointestinal Cancers Symposium.
- 20 Mar 2018 New trial record